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National Biotech Organization Chooses Philadelphia 
for Annual Meeting 
Tourists come to Philadelphia for its many attractions: Independence Hall, the Liberty Bell, and the 
biotechnology industry! BIO, the Biotechnology Industry Organization recently announced that it 
had selected Philadelphia as the site for its 10th annual International Biotechnology Meeting and 
Exhibition to be held June 8 - 13, 1996 at the Philadelphia Convention Center.  
 
"It puts the Philadelphia biotech community on the map," said Mark Kramer, executive director of 
the Technology Council of Greater Philadelphia. "The fact that BIO is coming here says volumes 
about what they think about the region and the depth of biotech companies here."  
 
Greater Philadelphia Chamber of Commerce president Charles Pizzi said: "The number one product 
of the Philadelphia area right now is the region's unequaled medical research industry and medical 
education. Having the national biotechnology convention in Philadelphia is an opportunity for us to 
show the world that we are second to none in these fields."  
 
BIO president, Carl Feldbaum, explained the selection, saying, "The BIO board of directors selected 
Philadelphia because it is one of America's foremost incubators for innovation in biotechnology. 
There are 180 biotech and pharmaceutical companies and 42,000 employees in the Philadelphia 
area, including a number of pioneering firms that are setting the pace for the development of 
biotech products in agriculture; environmental clean-up; and breakthrough treatments for aging 
diseases, AIDS, and other conditions."  
 
The Philadelphia area has been the perfect environment for the biotech and pharmaceutical industry 
with its leading medical centers and medical research institutes. The close proximity of industry and 
academia has led to many technology licensing agreements and research collaborations.  
 
In recent years, Philadelphia's biotech industry has been receiving national attention. The Route 202 
area has been called "The Medical Mile" with its many pharmaceutical and biotech firms. The large 
established pharmaceutical companies, such as SmithKline Beecham, with its U.S. headquarters in 
downtown Philadelphia, have led to many biotech spin-offs. Jeff Davidson, executive director of the 
Pennsylvania Biotechnology Association, says there are at least five to 10 new biotech start-ups 
each year.  
 
The biotech companies themselves have led to the creation of new service industry. One such 
company is Puresyn, Inc., started in 1993. Founded by former Rorer Pharmaceuticals executive 
Mickey Flynn, Puresyn purifies biotech and pharmaceutical products for other companies.  
While the biotech industry continues to grow, the availability of investment capital has slowed over 
the past couple of years. The tightening capital market came partly as a result of several biotech 
products failing to gain FDA approval. "Wall Street is taking a long-term view of biotechnology," said 
Jennifer Masse, director of the Technology Council's Healthcare Group.  
 
"Thankfully a certain realism has crept into the equation," said BIO's Feldbaum. "People now realize 
the difficulty in getting a drug to market."  
 
The tougher financial environment has been leading to an increase in partnering. Centocor is 
partnering with Indianapolis based Eli Lilly to market its anti-clotting drug, ReoPro. Cephalon and 
SmithKline Beecham are collaborating on stroke research. Cephalon is also partnering with the 
California-based biotech firm, Chiron, to develop nerve growth hormones and with North Jersey 
based Schering-Plough to research Alzheimer's disease. Rhone-Poulenc Rorer announced last year it 
was forming a biotech network with a group of biotech  
 
This collaborative spirit is expected to lead to major breakthroughs over the next few years. Jeff 
Davidson, of the Pennsylvania Biotech Association, is optimistic. "I believe we're heading towards an 
exciting future, and I think that the Philadelphia area is well-positioned to thrive in the 
biotechnology sector."  
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While the 1996 BIO convention is more than a year away, planning is already underway. For more 
information, call Mickey Flynn at 610-640-0800.  
 
